PARIS (Reuters) – Carmat, the artificial heart maker which this month got a 7 million euros ($7.40 million) lifeline to survive an imminent cash crunch, on Monday announced solid progress for its Aeson artificial heart device.
Carmat said it had performed seven Aeson implants as part of a clinical study in Paris and that it hoped to complete the study in 2025, in line with the company’s targets.
“This ramp-up is the result of growing experience in patient selection and attests to the steep learning curve of the surgical procedure,” said Professor Christian Latremouille, Director of Surgical Affairs at Carmat, in a press release.
The clinical study, called EFICAS, is a prospective study designed to include 52 patients eligible for transplants, currently enrolled by a network of six French cardiology centers, Carmat said.
The primary objective of the study is 180-day post-implantation survival without disabling stroke or successful heart transplant within 180 days of implantation, the company said.
The study also aims to assess state reimbursement of the device in France.
($1 = 0.9457 euros)
(Reporting by Sudip Kar-Gupta and Michal Aleksandrowicz; Editing by Jamie Freed and Janane Venkatraman)
EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email [email protected] Follow our WhatsApp verified Channel